In breast cancer, hypermethylation was identified in the plasma of patients with a more aggressive disease (stage IV) (52) and, in bladder cancer, FOXE1 methylation was suggested as one of the high-grade markers (53). Here, FOXE1 is linked to urinary bladder cancer.